These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?

InvestorPlace04-20

Small-cap stocks have underperformed their larger counterparts due to inflation and interest rates, but these three stocks bucked the trend. Dave (DAVE): Cash-strapped consumers are flocking to this ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428604016?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-20 02:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428604016","market":"us","top_or_hot":-1,"title":"These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?","media":"InvestorPlace","content":"<div>\n<p>Small-cap stocks have underperformed their larger counterparts due to inflation and interest rates, but these three stocks bucked the trend.\nDave (DAVE): Cash-strapped consumers are flocking to this ...</p>\n\n<a href=\"https://investorplace.com/2024/04/these-3-small-cap-stocks-are-up-304-in-2024-can-they-run-higher/\">Source Link</a>\n\n</div>\n","source":"investorplace_stock_picks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-20 02:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2024/04/these-3-small-cap-stocks-are-up-304-in-2024-can-they-run-higher/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Small-cap stocks have underperformed their larger counterparts due to inflation and interest rates, but these three stocks bucked the trend.\nDave (DAVE): Cash-strapped consumers are flocking to this ...</p>\n\n<a href=\"https://investorplace.com/2024/04/these-3-small-cap-stocks-are-up-304-in-2024-can-they-run-higher/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMCI","symbol_name":"超微电脑","start_time":0,"source_url":"https://investorplace.com/2024/04/these-3-small-cap-stocks-are-up-304-in-2024-can-they-run-higher/","article_id":"2428604016","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428604016","pubTimestamp":1713551420,"sourceInfo":{"source_id":"investorplace_stock_picks","name":"InvestorPlace stock picks"},"weMediaInfo":null,"summary":"Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game.","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMCI":"超微电脑","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","BK4551":"寇图资本持仓","PSQ":"纳指反向ETF","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","QLD":"纳指两倍做多ETF","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","QQQ":"纳指100ETF","NVDA":"英伟达","TQQQ":"纳指三倍做多ETF","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","CRBP":"Corbus Pharmaceuticals Holdings, Inc.","BMY":"施贵宝","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4529":"IDC概念","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc",".IXIC":"NASDAQ Composite","LU0056508442.USD":"贝莱德世界科技基金A2","SQQQ":"纳指三倍做空ETF","LU0080751232.USD":"富达环球多元动力基金A","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","DAVE":"Dave Inc","JNJ":"强生","LU0234572021.USD":"高盛美国核心股票组合Acc","SKYE":"Skye Bioscience Inc.","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","ADC":"艾格里房产","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","QID":"纳指两倍做空ETF","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","BK4559":"巴菲特持仓","BK4527":"明星科技股","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","BK4550":"红杉资本持仓","IE00BD6J9T35.USD":"NEUBERGER BERMAN NEXT GENERATION MOBILITY \"A\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC"},"translate_title":"这3只小盘股在2024年上涨了304%。他们能跑得更高吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DAVE":1,"JNJ":1,"NVDA":1,"CRBP":1,"BMY":1,"SKYE":1,"SMCI":1,"ADC":1,".IXIC":0.9,"TQQQ":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"QQQ":0.6,"SQQQ":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"Small-cap stocks have underperformed their larger counterparts due to inflation and interest rates, but these three stocks bucked the trend.\nDave (DAVE): Cash-strapped consumers are flocking to this digital bank though its main feature is more like a payday lending service.\nCorbus Pharmaceuticals Holdings (CRBP): Positive early-stage results in a space where multi-billion dollar deals were happening sent this cancer biotech soaring. \nSkye Biopharma (SKYE): Positive mid-stage trials were also the catalyst for this biotech, which used the opportunity to move from OTC trading to the Nasdaq exchange.\n \n\n\n\n \n\nSource: Shutterstock\n\n\n\nSmall-cap stocks tend to outperform their larger brethren over time. After several years of underperformance, it looked like the little guys were going to start winning again.\nInflation was moderating and the Federal Reserve was hinting it would cut interest rates at least three times this year. Beginning last October, the performance of the Russell 2000 index of small-cap stocks started pulling away from that of the S&P 500. But it wouldn’t last. Runaway government spending drove inflation higher and Fed chairman Jay Powell just intoned he no longer has “confidence” inflation is heading the right way. That means we won’t get interest rate cuts until at least December, according to some analysts.\nHigh interest rates are death to small businesses. Because they rely upon financing to fund their expansion, a rising rate environment absolutely kills the small business market. It’s why the Russell 2000 has been such a poor performer these past few years. It could also mean they will continue lagging in 2024.\nBut not all small companies are underachieving. In fact, some have been market standouts, even beating the likes of top tech headliners like Nvidia (NASDAQ:NVDA) and Super Micro Computer (NASDAQ:SMCI). The three small-cap stocks below are up at least 304% so far this year. Let’s see if they can keep running well ahead of the index.\nDave (DAVE)\nSource: Ricky Of The World / Shutterstock.comComedian Steve Martin used to joke that you needed to have a big, strong name for a bank because no one is going to put their money into Fred’s Bank. “Hi, I’m Fred. I have a bank.” Well, meet Dave (NASDAQ:DAVE). It’s a digital bank, or as it likes to call itself, a neobank. And people are flocking to its services. Operating revenue grew 26% last year and it finally turned profitable in the fourth quarter on an adjusted and GAAP basis.\nThe primary feature of Dave is its ExtraCash product, which provides small (up to $500) short-term loans without any interest, late fees or credit checks. Essentially Dave is a payday lender but at lower cost. While it doesn’t have any of the typical charges that come with a payday loan, it does charge a $1 per month subscription fee and it costs between $3 and $25 to access the loan immediately. There’s also the option to tip up to 15% (yeah, tipping culture is way out of hand if you’re tipping a bank). \nThe Los Angeles Times noted the typical payday lender had an interest rate of 414% if paid back within two weeks. An ExtraCash express loan, with tip, could have an interest rate of between 100% to well over 500%. Dave will also keep withdrawing money from your bank account until the loan is fully paid back.\nDave has over 13 million registered members, 10 million of whom have used at least one product. It added over 680,000 new members in the fourth quarter. The stock is up 304% in 2024. While it’s not a particularly good financial solution, Dave stock could go even higher as cash-tight consumers turn to alternative funding sources.\nCorbus Pharmaceuticals Holdings (CRBP)\nSource: MacroEcon / Shutterstock.comOncology biotech Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) was bouncing along the $5 per share range for months on end until this past January when it reported results from an early-phase trial for its antibody-drug conjugate (ADC) CRB-701. Following the report, Corbus’ stock quadrupled in value and today is up 515%.\nWhat likely got investors excited was the news stoked the fires of a potential acquisition. Not that Corbus has received any offers, but there have been numerous acquisitions in the space of late. Just this year Bristol-Myers Squibb (NYSE:BMY) paid $800 million upfront to China’s SystImmune as part of a deal for its ADC worth up to $8.4 billion; AbbVie (Nasdaq: ABBV) acquired ImmunoGen for $10 billion and Johnson & Johnson (NYSE:JNJ) bought Ambrx Biopharma for $2 billion.\nYet investors might be getting ahead of themselves. Those deals for ADCs were much further along the path than is CRB-701. For example, AbbVie got ImmunoGen’s ADC (which is FDA-approved) but also the rest of its oncology portfolio, too. Johnson & Johnson acquired numerous ADCs in the Ambrx deal.\nThere is potential for Corbus Pharmaceuticals to advance early but a 500% gain for such an early stage development seems like putting the cart before the horse. It does have other drugs under development too, but I still see the biotech’s shares retreating at some point.\nSkye Bioscience (SKYE)\nSource: Gorodenkoff / Shutterstock.comSkye Bioscience (NASDAQ:SKYE) is another biotech bounding higher this year on good, early phase news, though its drug candidate is further along in the clinical-trial stage. The biotech announced in February it had completed enrollment in a phase 2A study for its glaucoma drug SBI-100 Ophthalmic Emulsion (OE). It had targeted 54 patients for the study but got 56 enrolled and did it sooner than expected. It is now expecting topline data to be reported sometime in the second quarter.\nPreviously, Skye received clearance for its Investigational New Drug (IND) application with the Food & Drug Administration to begin phase 2 trials of nimacimab, a therapy for patients with obesity and chronic kidney disease.\nAll the positive news sent Skye Biopharma stock rocketing higher. It used the higher share price to raise $40 million in equity financing, which set the stock back a bit. However, it was able to also move the stock from the over-the-counter pink sheets to the Nasdaq exchange, which sent the stock jumping again. Today it 535% above the price it started 2024 at.\nOn the date of publication, Rich Duprey held a LONG position in ABBV and JNJ stock. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.\nRich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L’Express, and numerous other news outlets.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubmit\n\n\n\n\n\n\n\nArticle printed from InvestorPlace Media, https://investorplace.com/2024/04/these-3-small-cap-stocks-are-up-304-in-2024-can-they-run-higher/.\n©2024 InvestorPlace Media, LLC","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428604016"}